Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
On January 1 this year we offered a short list of just three “major” trials that we were hoping to see results from in 2011. One of these trials was the randomized, U.S.-based trial of “palliative expectant management” vs. radical surgery in men with localized prostate cancer (the Prostate Cancer Intervention Versus Observation Trial or [...]
Filed under: Management, Treatment | Tagged: expectant management, PIVOT, radical prostatectomy | Leave a Comment »
A story in Science Daily, based on new article in the Proceedings of the National Academy of Sciences (PNAS) , has suggested that blood levels of “prostasomes” may be a more accurate marker for prostate cancer risk that PSA levels in blood.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, Gleason score, marker, protasome | 1 Comment »
A re-analysis of data from patients enrolled in the Prostate Cancer Prevention Trial (PCPT) has now provided “the strongest evidence to date” that a diagnosis of symptomatic benign prostatic hyperplasia (BPH) is not associated with any increase in risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: benign prostatic hyperplasia, BPH, Diagnosis, risk | Leave a Comment »
A new article offers expert perspective on the relative merits of intermittent and continuous androgen deprivation therapy (ADT) in the treatment of men with metastatic prostate cancer or recurrence of disease following first- or second-line treatment.
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation, continuous, IADT, intermittent | 1 Comment »
A new report has suggested that there will be a 201 percent increase in the annual number of prostate cancer diagnoses in Canada between 2009 and 2021.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Canada, Diagnosis, incidence, mortality, risk | 1 Comment »
The ASCO Connection blog site today carries a piece by George Sledge, Jr., MD (the current president of the American Society of Clinical Oncology) entitled “Prostate cancer and value in cancer care.” Since Dr. Sledge is a highly experienced and fully trained medical oncologist and his father died of prostate cancer, we’ll just let Dr. Sledge [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Leave a Comment »
Back in June 2010, we reported on the initial results of SWOG 9921 — a trial that randomized 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", adjuvant, ADT, androgen deprivation therapy, surgery | 6 Comments »
A report in Family Medicine gives us some insight into the views of primary care physicians (PCPs) with respect to PSA testing for prostate cancer risk and the appropriate roles of the patient and the physician in the decision to have or not have PSA tests.
Filed under: Diagnosis, Risk | Tagged: decision-making, patient, physician, PSA, screening, shared, testing | Leave a Comment »
There is significant use of a variety of forms of complementary and alternative forms of medicine (CAM) among patients with localized prostate cancer. A new study in the Journal of Community Health has explored the prevalence and predictors of such behavior in a rural community setting.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: alternative, choice, complementary, quality of life | 1 Comment »
A media release issued by EDAP TMS SA – the developer and distributor of the Ablatherm® technology used in high-intensity focused ultrasound (HIFU) treatment of men with prostate cancer – states that a review of 15 years experience with Ablatherm technology will be published in the June issue of Current Urology Reports.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Ablatherm, HIFU, high-intensity focused ultrasound, review | Leave a Comment »
According to an announcement from the Veterans Administration (VA), it intends to roll out a new program called the Million Veterans Program or MVP which will allow pre-approved research teams to access (de-identified) genetic, military exposure, health, and lifestyle information on U.S. veterans together through one single database.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: genetics, lifestyle, outcomes, risk | 1 Comment »
GTx, Inc. has announced this morning that the company is planning a Phase IIb clinical trial of its oral, selective estrogen receptor agonist (GTx-758, also known as Capesaris™) as a potential first-line treatment for advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Uncategorized | Tagged: androgen deprivation therapy, Capesaris, GTx-758 | 2 Comments »
Pour les personnes qui parlent le français comme première langue, le contenu du The “New” Prostate Cancer InfoLink va maintenant être disponible en français à Solidarité Prostate InfoLink.
Filed under: Uncategorized | 1 Comment »
A recent article in the Journal of Urology offers some insight into the risk for a diagnosis of prostate cancer in a large, relatively young cohort of men undergoing regular health checks in the period between 1991 and 2008.
Filed under: Diagnosis, Management, Risk | Tagged: age, health, risk, U.S. Air Force | 2 Comments »
Monique Roobol and her colleagues continue to mine data from the ERSPC and other major trials in a serious attempt to describe processes that would allow us to identify the vast majority of clinically significant prostate cancers while avoiding the unnecessary diagnosis and over-treatment of indolent disease.
Filed under: Diagnosis, Risk | Tagged: biopsy, chemoprevention, combination, Diagnosis, dutasteride, risk, screening | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site